Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
492
datasets available to search
ShareScore release 0.9.0
Dataset results
492 results for “EGFR mutations;”
Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations
ClinicalTrials.gov study NCT02759614. IPD Sharing: YES. Countries: 1. Publications: 3.
Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma
ClinicalTrials.gov study NCT04201756. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (
ClinicalTrials.gov study NCT01081496. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Non-interventional, Prospective Study to Determine Prevalence of EGFR Mutations in Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT04742192. IPD Sharing: YES. Countries: 15. Publications: 1.
Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov study NCT02206763. IPD Sharing: Not stated. Countries: 1. Publications: 1.
BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT03386955. IPD Sharing: NO. Countries: 1. Publications: 3.
Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations
ClinicalTrials.gov study NCT04923906. IPD Sharing: NO. Countries: 1. Publications: 0.
Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients
ClinicalTrials.gov study NCT03137264. IPD Sharing: NO. Countries: 2. Publications: 11.
Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study
ClinicalTrials.gov study NCT04122833. IPD Sharing: NO. Countries: 1. Publications: 5.
A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation
ClinicalTrials.gov study NCT06102928. IPD Sharing: NO. Countries: 1. Publications: 8.
Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA
ClinicalTrials.gov study NCT02769286. IPD Sharing: NO. Countries: 1. Publications: 3.
Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC
ClinicalTrials.gov study NCT03711422. IPD Sharing: NO. Countries: 1. Publications: 2.
Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT02959749. IPD Sharing: NO. Countries: 1. Publications: 1.
Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation
ClinicalTrials.gov study NCT01405079. IPD Sharing: UNDECIDED. Countries: 1. Publications: 4.
Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer
ClinicalTrials.gov study NCT02716311. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Dacomitinib in Lung Cancer With Uncommon EGFR Mutations
ClinicalTrials.gov study NCT04504071. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)
ClinicalTrials.gov study NCT03810066. IPD Sharing: Not stated. Countries: 1. Publications: 1.
INHERIT EGFR - Studying Germline EGFR Mutations
ClinicalTrials.gov study NCT01754025. IPD Sharing: Not stated. Countries: 1. Publications: 2.
A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acq
ClinicalTrials.gov study NCT02495233. IPD Sharing: NO. Countries: 1. Publications: 0.
HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT04676477. IPD Sharing: YES. Countries: 4. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.